|1.||Shibata, Takahiro: 3 articles (01/2015 - 07/2003)|
|2.||Surh, Young-Joon: 3 articles (11/2011 - 12/2006)|
|3.||Na, Hye-Kyung: 3 articles (11/2011 - 12/2006)|
|4.||Cuzzocrea, Salvatore: 3 articles (08/2008 - 02/2004)|
|5.||Evers, B Mark: 3 articles (03/2004 - 01/2002)|
|6.||Hashimoto, Koji: 3 articles (03/2004 - 01/2002)|
|7.||Li, Jingjing: 2 articles (01/2015 - 01/2014)|
|8.||Wang, Fan: 2 articles (01/2015 - 01/2014)|
|9.||Zhou, Yingqun: 2 articles (01/2015 - 01/2014)|
|10.||Lu, Jie: 2 articles (01/2015 - 01/2014)|
|1.||Breast Neoplasms (Breast Cancer)
08/15/2010 - "In the present study, we investigate the effect of the electrophilic prostaglandin 15d-PGJ2 (15-deoxy-Delta12,14-prostaglandin J2) on metastatic properties of breast cancer cells. "
01/01/2015 - "15d-PGJ2 exerted its effects on breast cancer and bone cells via PPARγ-independent pathways. "
12/01/2006 - "In this work, we found that treatment of human breast cancer (MCF-7) cells with 15d-PGJ2 led to time-dependent increases in the expression of HO-1. "
01/01/2015 - "Therefore, 15d-PGJ2 may be beneficial for the prevention and treatment of breast cancer-associated bone diseases. "
01/01/2015 - "15d-PGJ2 dose-dependently inhibited viability, migration, invasion, and parathyroid hormone-related protein (PTHrP) production in MDA-MB-231 breast cancer cells. "
|2.||Septic Shock (Toxic Shock Syndrome)
07/01/2005 - "This study was designed to examine the effect and the molecular mechanisms of 15d-PGJ2 on tissue neutrophil infiltration and survival in endotoxic shock. "
07/01/2005 - "Our data demonstrate that 15d-PGJ2 ameliorates endotoxic shock most likely through repressing the proinflammatory pathway of NF-kappaB and enhancement of the cytoprotective heat shock response."
03/15/2015 - "Furthermore, in a murine anthrax infection model, 15d-PGJ2 reversed anthrax lethal toxin-mediated NLRP1-dependent resistance. "
05/05/2014 - "Therefore, the use of 15d-PGJ2 may be a new method for the prevention or treatment of inflammatory changes to cancer caused by HBV infection in liver cells. "
12/01/2011 - "MTT assay was used to detect the rate of viral suppression, and the protective effects of 15d-PGJ2 and rosiglitazone on A549 cells induced by RSV infection for 48 h. "
12/01/2011 - "The effects of 15d-PGJ2 and rosiglitazone on change of CPE of A549 cells induced by RSV infection for 48 h were observed, too. "
12/01/2011 - "A549 cells interfered by 15d-PGJ2 (5 -25 micromol/L) and rosiglitazone (10-50 micromol/L) did not show obvious CPE, MTT assay also showed that the survival rate of A549 cells induced by RSV infection with PPARgamma agonists added, was significantly higher than that of RSV infection without PPARgamma agonists added, the difference was statistically significant (P < 0.01), but comparision between the two drugs showed no statistical significance. "
09/01/2005 - "Concurrently, NF-kappaB was greatly activated in myocarditis; this activation was blocked in the 15d-PGJ2 treated and PIO treated groups. "
09/01/2005 - "These results suggest that PPAR-gamma activators such as 15d-PGJ2 and PIO may have the potential to modulate human inflammatory heart diseases such as myocarditis."
09/01/2005 - "Administration of 15d-PGJ2 and PIO greatly reduced the severity of myocarditis and suppressed myocardial mRNA and protein expression of inflammatory cytokines in rats with EAM. "
|1.||Messenger RNA (mRNA)
|3.||NF-kappa B (NF-kB)
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Peroxisome Proliferator-Activated Receptors (PPAR)